John O Mascarenhas

69PUBLICATIONS
195CO-AUTHORS
Regenerative medicine (incl. stem cells)Innate immunityProteins and peptidesMedical virologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (69)

|Jun 02, 2026
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

|May 29, 2026
Interferon in early MF: intersection of biology and evidence.

|May 18, 2026
Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients.

|Apr 15, 2026
Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR), With del(5q) and Double Minutes Containing Chromosomal Segment 11q24 Leading to Amplification and Expression of FLI1.

Satomi Hiya, Joseph Tripodi, John Mascarenhas

|Mar 17, 2026
Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.

John O Mascarenhas, Laura Maria Fogliatto, Steven D Green

|Feb 03, 2026
Sequential treatment with ruxolitinib and imetelstat effectively depletes myelofibrosis hematopoietic stem and progenitor cells.

Xiaoli Wang, Andrew Davis, Cing Siang Hu

Pageof 12

Frequent Collaborators

9 joint publications

Vikas K Gupta

8 joint publications

Alessandro Maria Vannucchi

8 joint publications

Jean-Jacques Kiladjian

7 joint publications

Srdan Verstovsek